Compound class:
Synthetic organic
Comment: Compound 2-2c is a selective inhibitor of DYRK1A whose chemical structure is derived from that of the DYRK1 kinase inhibitor harmine [1]. It was developed for potential to promote pancreatic β-cell proliferation as a novel mechanism to be applied to the treatment of type 1 diabetes. It produces predicted effects on β-cells in vitro and in vivo.
See also GNF2133, which is a selective DYRK1A inhibitor with a different chemical scaffold [2]. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Compound has an improved kinase selectivity profile compared to harmine [1] as determined using the DiscoverX KINOMEscan platform. In this screen, in addition to DYRK1A, 10 μM 2-2c strongly inhibited (by >90%) CLK1, CLK2, DYRK1B, DYRK2, HASPIN, HIPK2 and PIK4CB (PI4KB). 2-2c cannot cross the blood-brain-barrier, and in any event has low activity across a range of known harmine off-targets. Harmine is known to inhibit MAO-A, and 2-2c retains this activity (both compounds inhibit MAO-A by ≥95%). |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|